Title: AMEND S e n ate Bill No. 1414 House Bill No. 1242*
Official Title: AMEND S e n ate Bill No. 1414 House Bill No. 1242*
Number of Sections: 5
Source: versions - Amendment SA0379
Media Type: application/pdf
Strikethrough Detection: 4 sections found

================================================================================

Section 1:
Senate Finance, Ways, and Means 1
Amendment No. 2 to SB1414
Watson
Signature of Sponsor
by deleting all language after the enacting clause and substituting:

Section 2:
SECTION 1. Tennessee Code Annotated, Title 47, Chapter 18, Part 1, is amended by
adding the following new section:
47-18-136.
(a) On or after July 1, 2025, a drug manufacturer or their agent or affiliate, shall
not, either directly or indirectly:
(1) Impose additional requirements or limitations on a 340B entity,
including requiring the submission of any health information, claims or utilization
data, purchasing data, payment data, or other data as a condition for allowing the
acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity unless
such data submission is explicitly required by the United States department of
health and human services or applicable state law;
(2) Require a 340B entity to reverse, resubmit, or clarify a claim after the
initial adjudication unless these actions are in the normal course of business and
not related to the 340B program;
(3) Impose any requirements relating to inventory management systems
of 340B drugs, unless such requirement is required by the United States
department of health and human services or applicable state law;
(4) Impose any requirement relating to the frequency, duration, or scope
of audits that are not imposed on pharmacies or providers that are not 340B
entities;
SA0379
006851
- 1 -
(5) Impose requirements relating to accreditation, recertification,
credentialing, or recredentialing that are not imposed on pharmacies or providers
that are not 340B entities; or
(6) Impose any requirement determined by the attorney general and
reporter to interfere with the ability of a 340B entity to access discounts provided
under the 340B program.
(b) On or after July 1, 2025, a person or entity that contracts with a 340B entity
to dispense 340B drugs or to administer a 340B entity's participation in the 340B
program shall:
(1) Not interfere with, prohibit, restrict, or limit a 340B entity's contracts or
prospective business relationships with another person or entity;
(2) Not deny, restrict, prohibit, or otherwise interfere with a 340B entity's
choice of 340B drugs acquired, delivered, or otherwise distributed; or
(3) Exclude claims from 340B entities which would result in a net loss to
the covered entity.
(c) A drug manufacturer, or its agent or affiliate, shall not, either directly or
indirectly, deny, impose any restrictions, prohibitions, discriminate against, or otherwise
limit the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity or
other location that is under contract with, or otherwise authorized by, a 340B entity to
receive 340B drugs on behalf of the 340B entity unless such receipt is prohibited by the
United States department of health and human services or applicable state law. This
subsection (c) does not apply to any requirements, prohibitions, limitations, or
restrictions in place on or before June 1, 2025.
(d)
(1) A violation of subsection (a) or (c) constitutes an unfair or deceptive
act or practice affecting trade or commerce and is a violation of this part;
- 2 - 006851
provided, that a civil penalty may be assessed in the amount of fifty thousand
dollars ($50,000) per violation.
(2) Each package of 340B drugs applicable to a violation of subsection
(a) or (c) constitutes a separate violation.
(e) This section must not be construed or applied to be in conflict with or less
restrictive than:
(1) Applicable federal law and regulations, including limited distribution of
a drug required under 21 U.S.C. § 355-1; or
(2) Another law of this state if the law is compatible with applicable
federal law, including, but not limited to, title 39, chapter 15, part 2; title 68,
chapter 1, part 1; title 68, chapter 33; and any other law related to a patient's
citizenship status.
(f) This section does not apply to:
(1) The TennCare program administered under the Medical Assistance
Act of 1968, compiled in title 71, chapter 5, part 1, or a successor medicaid
program;
(2) The CoverKids Act of 2006, compiled in title 71, chapter 3, part 11, or
a successor program; or
(3) The prescription drug discount plan described in title 56, chapter 57,
or a successor program.
(g) As used in this section:
(1) "340B drug" means a drug that is a covered outpatient drug within the
meaning of 42 U.S.C. § 256b; is eligible for any offer for reduced prices by a
manufacturer under 42 U.S.C. § 256b(a)(1); and is purchased by a 340B entity or
would have been purchased by a 340B entity but for a restriction or limitation
described in § 56-7-3119(b);
- 3 - 006851
(2) "340B entity" means a covered entity participating in the federal 340B
drug discount program, as defined in section 340B of the Public Health Service
Act, 42 U.S.C. § 256b, including the entity's pharmacy or pharmacies;
(3) "Claim" means a request from a 340B entity to be reimbursed for the
cost of filling, refilling, or administering a prescription drug or for providing a
medical supply or device;
(4) "Health information" means any information, including demographic
information collected from an individual or a group of individuals, that:
(A) Is created or received by a healthcare provider, pharmacy,
health plan, employer, or healthcare clearinghouse; and
(B) Relates to the past, present, or future physical or mental
health or condition of an individual, the provision of health care to an
individual, or the past, present, or future payment for the provision of
health care to an individual; and
(5) "Package" has the same meaning as defined in 21 U.S.C. §
360eee(11)(A).

Section 3:
SECTION 2. Tennessee Code Annotated, Section 47-18-104(b), is amended by adding
the following new subdivision:
(68) Violating § 47-18-136.

Section 4:
SECTION 3. If any provision of this act or its application to any person or circumstance
is held invalid, then the invalidity does not affect other provisions or applications of the act that
can be given effect without the invalid provision or application, and to that end, the provisions of
this act are severable.

Section 5:
SECTION 4. This act takes effect upon becoming a law, the public welfare requiring it.
- 4 - 006851
[DELETED:  a H]
[DELETED:  -0]
[DELETED:  -0(]
[DELETED:  -0]


================================================================================

Raw Text:
Senate Finance, Ways, and Means 1
Amendment No. 2 to SB1414
Watson
Signature of Sponsor
AMEND S e n ate Bill No. 1414 House Bill No. 1242*
by deleting all language after the enacting clause and substituting:
SECTION 1. Tennessee Code Annotated, Title 47, Chapter 18, Part 1, is amended by
adding the following new section:
47-18-136.
(a) On or after July 1, 2025, a drug manufacturer or their agent or affiliate, shall
not, either directly or indirectly:
(1) Impose additional requirements or limitations on a 340B entity,
including requiring the submission of any health information, claims or utilization
data, purchasing data, payment data, or other data as a condition for allowing the
acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity unless
such data submission is explicitly required by the United States department of
health and human services or applicable state law;
(2) Require a 340B entity to reverse, resubmit, or clarify a claim after the
initial adjudication unless these actions are in the normal course of business and
not related to the 340B program;
(3) Impose any requirements relating to inventory management systems
of 340B drugs, unless such requirement is required by the United States
department of health and human services or applicable state law;
(4) Impose any requirement relating to the frequency, duration, or scope
of audits that are not imposed on pharmacies or providers that are not 340B
entities;
SA0379
006851
- 1 -

(5) Impose requirements relating to accreditation, recertification,
credentialing, or recredentialing that are not imposed on pharmacies or providers
that are not 340B entities; or
(6) Impose any requirement determined by the attorney general and
reporter to interfere with the ability of a 340B entity to access discounts provided
under the 340B program.
(b) On or after July 1, 2025, a person or entity that contracts with a 340B entity
to dispense 340B drugs or to administer a 340B entity's participation in the 340B
program shall:
(1) Not interfere with, prohibit, restrict, or limit a 340B entity's contracts or
prospective business relationships with another person or entity;
(2) Not deny, restrict, prohibit, or otherwise interfere with a 340B entity's
choice of 340B drugs acquired, delivered, or otherwise distributed; or
(3) Exclude claims from 340B entities which would result in a net loss to
the covered entity.
(c) A drug manufacturer, or its agent or affiliate, shall not, either directly or
indirectly, deny, impose any restrictions, prohibitions, discriminate against, or otherwise
limit the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity or
other location that is under contract with, or otherwise authorized by, a 340B entity to
receive 340B drugs on behalf of the 340B entity unless such receipt is prohibited by the
United States department of health and human services or applicable state law. This
subsection (c) does not apply to any requirements, prohibitions, limitations, or
restrictions in place on or before June 1, 2025.
(d)
(1) A violation of subsection (a) or (c) constitutes an unfair or deceptive
act or practice affecting trade or commerce and is a violation of this part;
- 2 - 006851

provided, that a civil penalty may be assessed in the amount of fifty thousand
dollars ($50,000) per violation.
(2) Each package of 340B drugs applicable to a violation of subsection
(a) or (c) constitutes a separate violation.
(e) This section must not be construed or applied to be in conflict with or less
restrictive than:
(1) Applicable federal law and regulations, including limited distribution of
a drug required under 21 U.S.C. § 355-1; or
(2) Another law of this state if the law is compatible with applicable
federal law, including, but not limited to, title 39, chapter 15, part 2; title 68,
chapter 1, part 1; title 68, chapter 33; and any other law related to a patient's
citizenship status.
(f) This section does not apply to:
(1) The TennCare program administered under the Medical Assistance
Act of 1968, compiled in title 71, chapter 5, part 1, or a successor medicaid
program;
(2) The CoverKids Act of 2006, compiled in title 71, chapter 3, part 11, or
a successor program; or
(3) The prescription drug discount plan described in title 56, chapter 57,
or a successor program.
(g) As used in this section:
(1) "340B drug" means a drug that is a covered outpatient drug within the
meaning of 42 U.S.C. § 256b; is eligible for any offer for reduced prices by a
manufacturer under 42 U.S.C. § 256b(a)(1); and is purchased by a 340B entity or
would have been purchased by a 340B entity but for a restriction or limitation
described in § 56-7-3119(b);
- 3 - 006851

(2) "340B entity" means a covered entity participating in the federal 340B
drug discount program, as defined in section 340B of the Public Health Service
Act, 42 U.S.C. § 256b, including the entity's pharmacy or pharmacies;
(3) "Claim" means a request from a 340B entity to be reimbursed for the
cost of filling, refilling, or administering a prescription drug or for providing a
medical supply or device;
(4) "Health information" means any information, including demographic
information collected from an individual or a group of individuals, that:
(A) Is created or received by a healthcare provider, pharmacy,
health plan, employer, or healthcare clearinghouse; and
(B) Relates to the past, present, or future physical or mental
health or condition of an individual, the provision of health care to an
individual, or the past, present, or future payment for the provision of
health care to an individual; and
(5) "Package" has the same meaning as defined in 21 U.S.C. §
360eee(11)(A).
SECTION 2. Tennessee Code Annotated, Section 47-18-104(b), is amended by adding
the following new subdivision:
(68) Violating § 47-18-136.
SECTION 3. If any provision of this act or its application to any person or circumstance
is held invalid, then the invalidity does not affect other provisions or applications of the act that
can be given effect without the invalid provision or application, and to that end, the provisions of
this act are severable.
SECTION 4. This act takes effect upon becoming a law, the public welfare requiring it.
- 4 - 006851

[DELETED:  a H]
[DELETED:  -0]
[DELETED:  -0(]
[DELETED:  -0]